Company: PCRX
Filing Date: 2025-08-05
Form Type: 10-Q
Source: 0001396814-25-000102
Chunk: 69

Company: Pacira BioSciences, Inc.
Filing Date: 2025-08-05
Form: 10-Q
Item: Part I, Item 1
Chunk 69
---
 16%. At December 31, 2024, three wholesalers each accounted for over 10% of the Company’s accounts receivable, at 34%, 18% and 16%. For additional information regarding the Company’s wholesalers, see Note 2, Summary of Significant Accounting Policies. EXPAREL and ZILRETTA revenues are primarily derived from major wholesalers and specialty distributors that generally have significant cash resources. The Company performs ongoing credit evaluations of its customers as warranted and generally does not require collateral. Allowances for credit losses on the Company’s accounts receivable are maintained based on historical payment patterns, current and estimated future economic conditions, aging of accounts receivable and its write-off history. As of June 30, 2025 and December 31, 2024, there were $0.5 million and $0.4 million of allowances for credit losses on the Company’s accounts receivable, respectively.

Pacira BioSciences, Inc.  |  Q2 2025 Form 10-Q  |  Page 26

NOTE 11—STOCKHOLDERS’ EQUITY

Accumulated Other Comprehensive IncomeThe following tables illustrate the changes in the balances of the Company’s accumulated other comprehensive income for the periods presented (in thousands):Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive IncomeBalance at December 31, 2024$190 $153 $343    Net unrealized loss on investments, net of tax(131)— (131)   Foreign currency translation adjustments— 3,850 3,850 Balance at June 30, 2025$59 $4,003 $4,062 Net Unrealized Gain (Loss) From Available-For-Sale InvestmentsUnrealized Foreign Currency TranslationAccumulated Other Comprehensive IncomeBalance at December 31, 2023$124 $123 $247    Net unrealized loss on investments, net of tax (1)(160)— (160)   Foreign currency translation adjustments— 18 18 Balance at June 30, 2024$(36)$141 $105 (1) Net of a nominal and $0.1 million tax benefit for each of the six months ended June 30, 2025 and 2024. Share Repurchase ProgramsOn May 7, 2024, the Company announced that its Board of Directors